HRMY
Harmony Biosciences Holdings, Inc.
$30.15
-0.34
(-1.12%)
Mkt Cap
1.75B
Volume
384,764
52W Range
25.52-40.87
Sector
Healthcare
Beta
0.96
EPS (TTM)
2.52
P/E Ratio
11.96
Revenue (TTM)
899.11M
Rev Growth (5Y)
+40.3%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$131.44
Undervalued · Strong
77.1% below fair value
AlphaQuality · Grade
A-
Platform & Compounding FCF
80.6 / 100 composite
Company Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 868.45M | 714.73M | 582.02M | 437.86M | 305.44M | 159.74M | 6.00M | 0 |
| Net Income | 158.69M | 145.49M | 128.85M | 181.47M | 34.60M | (36.94M) | (151.98M) | (39.90M) |
| EPS | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 | -1.12 | -2.94 | -1.42 |
| Free Cash Flow | 347.89M | 218.67M | 219.07M | 144.29M | 98.26M | (4.99M) | (75.58M) | (40.14M) |
| FCF / Share | 6.05 | 3.84 | 3.68 | 2.44 | 1.71 | -0.09 | -1.19 | -0.82 |
| Operating CF | 348.20M | 219.82M | 219.39M | 144.47M | 98.56M | (2.98M) | (75.44M) | (38.80M) |
| Total Assets | 1.27B | 999.20M | 811.45M | 673.87M | 433.44M | 427.07M | 106.70M | 89.28M |
| Total Debt | 239.58M | 181.41M | 193.57M | 191.65M | 195.74M | 194.25M | 97.95M | 324.20M |
| Cash & Equiv | 752.50M | 453.00M | 311.66M | 243.78M | 234.31M | 228.63M | 24.46M | 83.52M |
| Book Value | 870.22M | 659.15M | 466.99M | 402.84M | 186.51M | 97.18M | (11.59M) | 81.53M |
| Return on Equity | 0.18 | 0.22 | 0.28 | 0.45 | 0.19 | -0.38 | N/A | -0.49 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 215.39M | 243.78M | 239.46M | 200.49M | 184.73M | 201.27M | 186.04M | 172.81M | 154.62M | 168.41M | 160.27M | 134.22M |
| Net Income | 32.49M | 22.49M | 50.87M | 39.78M | 45.56M | 49.48M | 46.09M | 11.59M | 38.33M | 26.61M | 38.46M | 34.30M |
| EPS | 0.56 | 0.39 | 0.88 | 0.69 | 0.80 | 0.87 | 0.81 | 0.20 | 0.68 | 0.46 | 0.64 | 0.57 |
| Free Cash Flow | 27.76M | 126.04M | 108.66M | 79.32M | 33.86M | 75.05M | 70.50M | 41.98M | 31.14M | 76.56M | 63.10M | 36.86M |
| FCF / Share | 0.48 | 2.19 | 1.86 | 1.38 | 0.59 | 1.31 | 1.24 | 0.74 | 0.55 | 1.31 | 1.05 | 0.61 |
| Operating CF | 27.76M | 126.15M | 108.73M | 79.33M | 33.99M | 75.56M | 70.50M | 42.62M | 31.14M | 76.67M | 63.10M | 37.06M |
| Total Assets | 1.27B | 1.27B | 1.21B | 1.11B | 1.06B | 999.20M | 928.13M | 858.38M | 846.99M | 811.45M | 777.77M | 760.18M |
| Total Debt | 206.51M | 239.58M | 169.73M | 173.37M | 177.46M | 181.41M | 185.24M | 189.06M | 193.06M | 196.09M | 199.72M | 193.72M |
| Cash & Equiv | 589.40M | 752.50M | 647.00M | 546.05M | 489.00M | 453.00M | 387.37M | 317.30M | 332.98M | 311.66M | 324.60M | 317.42M |
| Book Value | 910.35M | 870.22M | 835.12M | 773.08M | 720.52M | 659.15M | 596.80M | 538.58M | 515.39M | 466.99M | 481.33M | 485.17M |
| Return on Equity | 0.04 | 0.03 | 0.06 | 0.05 | 0.06 | 0.08 | 0.08 | 0.02 | 0.07 | 0.06 | 0.08 | 0.07 |
HRMY News
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
HRMY or ARGX: Which Is the Better Value Stock Right Now?
Wall Street Analysts Think Harmony Biosciences (HRMY) Could Surge 34.81%: Read This Before Placing a Bet
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
Harmony Biosciences Eyes $1B WAKIX Runway, Teases 2026 Pipeline Catalysts at Needham Conference
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript